Lupus · 2002 · 136 citations · 42 references
MedicinePharmacologyPharmacotherapyAutoimmunityInflammationRheumatologyAutoimmune DiseasesImmune-mediated Organ DamageSystemic Lupus ErythematosusAntimalarial AgentsCyclophosphamide-based TherapyHydroxychloroquine TherapyHydroxychloroquine TreatmentLogistic RegressionOrgan Damage AssessmentSystemic Lupus Erythematosus Associations
Systemic lupus erythematosus-associated irreversible organ/system damage was previously associated with various clinical and demographic features. We analysed the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI) in a cohort of 151 Israeli patients followed for a mean (+/- s.d.) period of 45.7 +/- 37.4 months. Mean score of SLICC/ACR DI at the first and last encounters were 0.17 +/- 64 and 1.64 +/- 2.1, respectively (P < 0.0001). Multiple logistic regression analyses disclosed a statistically significant positive correlation with corticosteroid and cyclophosphamide therapy. Hydroxychloroquine therapy was significantly associated with lower SLICC/ACR DI. Although the size of our study group did not allow us to find specific organs/systems which were associated with the protective effect of hydroxychloroquine, we suggest this is due to the antiatherogenic effects attributed to antimalarial therapy in SLE.
42
The 1982 revised criteria for the classification of systemic lupus erythematosus
Eng M. Tan, Alan S. Cohen, James F. Fries et al. · Arthritis & Rheumatism · 1982 · 14.6K citations
Derivation of the sledai. A disease activity index for lupus patients
Claire Bombardier, Dafna D. Gladman, Murray B. Urowitz et al. · Arthritis & Rheumatism · 1992 · 4.6K citations
S Manzi, Elaine N. Meilahn, Joan E. Rairie et al. · American Journal of Epidemiology · 1997 · 1.8K citations
Dafna D. Gladman, Murray B. Urowitz, Charles H. Goldsmith et al. · Arthritis & Rheumatism · 1997 · 758 citations